

### REMARKS

Claims 1-14, 16, 17, and 24-27 are pending in this application prior to entry of this Amendment. By way of this Amendment, claims 2, 3, and 24-27 have been cancelled, and claims 1, 6, and 8 have been amended. No claims have been added. No new matter has been added by the amendments.


The instant application was placed under a telephonic restriction requirement by the Office on April 16, 2008. At that time, the Examiner required restriction between three groups. Applicants elected Group I of the groups presented by the Examiner. **Applicants respectfully request that the Examiner specifically memorialize the groups of the restriction requirement, and acknowledge Applicants election, in the next Official Action so that the requirement will be of record.**

The claims have been amended to remove subject matter outside the scope of elected Group I. Support for the amendments is provided generally in the originally-filed specification and examples. Most of the amendments were suggested by the Examiner by way of the restriction requirement.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

  
\_\_\_\_\_  
Scott Young  
Attorney for Applicant  
Registration No. 45,582

Date: April 25 2008  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-8160  
Facsimile: 919-483-7988